Factors associated with poor pulmonary function: Cross-sectional analysis of data from the ERCF

European Respiratory Journal

Volumn 18, Issue 2, 2001, Pages 298-305

  Navarro, J ^a   Rainisio, M ^a   Harms, H K ^a   Hodson, M E ^a   Koch, C ^a   Mastella, G ^a   Strandvik, B ^a   McKenzie, S G ^a  

^a HÔPITAL ROBERT DEBRÉ   (France)

Author keywords

Cystic fibrosis; Pulmonary function; Registry; Respiratory function tests

Indexed keywords

BRONCHODILATING AGENT; CORTICOSTEROID; DORNASE ALFA; INSULIN; NONSTEROID ANTIINFLAMMATORY AGENT; ORAL ANTIDIABETIC AGENT; OXYGEN; PANCREAS ENZYME;

ADOLESCENT; ADULT; AGE; ARTICLE; ASPERGILLUS; ASSISTED VENTILATION; BODY WEIGHT; BRONCHOPULMONARY ASPERGILLOMA; BURKHOLDERIA CEPACIA; CANDIDA; CONTROLLED STUDY; CYSTIC FIBROSIS; DIABETES MELLITUS; DISEASE ASSOCIATION; DRUG USE; EXERCISE; FEMALE; FORCED EXPIRATORY VOLUME; GASTROESOPHAGEAL REFLUX; GENDER; HAEMOPHILUS INFLUENZAE; HEMOPTYSIS; HUMAN; LUNG CLEARANCE; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; NOSE POLYP; NUTRITION; PNEUMOTHORAX; PORTAL HYPERTENSION; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; REGISTER; STAPHYLOCOCCUS AUREUS; STEROID THERAPY; SUPPLEMENTATION; SYMPTOM;

ADOLESCENT; ADULT; CHILD; CROSS-SECTIONAL STUDIES; CYSTIC FIBROSIS; EUROPE; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; INTERNATIONAL COOPERATION; LONGITUDINAL STUDIES; MALE; RESPIRATORY FUNCTION TESTS; RISK FACTORS;

EID: 0034891408     PISSN: 09031936     EISSN: None     Source Type: Journal    
DOI: 10.1183/09031936.01.00068901     Document Type: Article

References (34)

1. The changing epidemiology of cystic fibrosis
2. Cystic fibrosis: Molecular biology and therapeutic implications
3. The cystic fibrosis transmembrane conductance regulator
4. Clinical features, survival rate, and prognostic factors in young adults with cystic fibrosis
5. Determinants of mortality in cystic fibrosis in Canada 1970-89
6. Prediction of mortality in patients with cystic fibrosis
7. International practice patterns by age and severity of lung disease in cystic fibrosis: Data from the Epidemiologic Registry of Cystic Fibrosis (ERCF)
8. Allergic bronchopulmonary aspergillosis in cystic fibrosis. A European epidemiological study
9. Changes in the normal maximal expiratory flow-volume curve with growing and aging
10. Physical growth: National Center for Health Statistics percentiles
11. A comparison of survival, growth and pulmonary function in patients with cystic fibrosis in Boston and Toronto
12. Prognosis in cystic fibrosis
13. Growth status in children with cystic fibrosis based on the National Cystic Fibrosis Patient Registry data: Evaluation of various criteria used to identify malnutrition
14. Improved growth and clinical, nutritional, and respiratory changes in response to nutritional therapy in cystic fibrosis
15. Enteral-tube feeding as adjunct therapy in malnourished patients with cystic fibrosis: A clinical study and literature review
16. The impact of nutrition in cystic fibrosis: A review
17. Diabetes mellitus associated with cystic fibrosis
18. Influence of the development of diabetes on clinical status in patients with cystic fibrosis
19. Desensitization to Aspergillus and allergic bronchopulmonary aspergillosis in a cystic fibrosis population
20. Prevalence of allergic bronchopulmonary aspergillosis at enrollment into the epidemiologic study of cystic fibrosis
21. Liver transplantation in paediatrics: Indications, contraindications and pretransplant management
22. Prognosis in cystic fibrosis
23. Natural history of liver disease in cystic fibrosis
24. Clinical characteristics and genotype analysis of patients with cystic fibrosis and nasal polyposis requiring surgery
25. Microbiological parameters and clinical evolution in cystic fibrosis
26. Haemophilus from the lower respiratory tract of patients with cystic fibrosis
27. Microbiology of lung infections in cystic fibrosis patients
28. Mucoviscidosis. Antibiotic management
29. Prevention and treatment of infections in cystic fibrosis
30. Prognosis in cystic fibrosis treated with continuous flucloxacillin from the neonatal period
31. To Keflex or not to Keflex: Long-term antibiotics in CF
32. A randomized, placebo-controlled trial of two years' treatment with dornase alfa (Pulmozyme®) in cystic fibrosis patients aged 6-10 years with early lung disease
33. Exercise conditioning and cardiopulmonary fitness in cystic fibrosis. The effects of a three-month supervised running program